BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36618262)

  • 1. Multiplex HDR for disease and correction modeling of SCID by CRISPR genome editing in human HSPCs.
    Iancu O; Allen D; Knop O; Zehavi Y; Breier D; Arbiv A; Lev A; Lee YN; Beider K; Nagler A; Somech R; Hendel A
    Mol Ther Nucleic Acids; 2023 Mar; 31():105-121. PubMed ID: 36618262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas9 engineering of the RAG2 locus via complete coding sequence replacement for therapeutic applications.
    Allen D; Knop O; Itkowitz B; Kalter N; Rosenberg M; Iancu O; Beider K; Lee YN; Nagler A; Somech R; Hendel A
    Nat Commun; 2023 Oct; 14(1):6771. PubMed ID: 37891182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration.
    Bloomer H; Smith RH; Hakami W; Larochelle A
    Mol Ther; 2021 Apr; 29(4):1611-1624. PubMed ID: 33309880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells.
    Brault J; Liu T; Liu S; Lawson A; Choi U; Kozhushko N; Bzhilyanskaya V; Pavel-Dinu M; Meis RJ; Eckhaus MA; Burkett SS; Bosticardo M; Kleinstiver BP; Notarangelo LD; Lazzarotto CR; Tsai SQ; Wu X; Dahl GA; Porteus MH; Malech HL; De Ravin SS
    Front Immunol; 2022; 13():1067417. PubMed ID: 36685559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9-Based Disease Modeling and Functional Correction of Interleukin 7 Receptor Alpha Severe Combined Immunodeficiency in T-Lymphocytes and Hematopoietic Stem Cells.
    Rai R; Steinberg Z; Romito M; Zinghirino F; Hu YT; White N; Naseem A; Thrasher AJ; Turchiano G; Cavazza A
    Hum Gene Ther; 2024 Apr; 35(7-8):269-283. PubMed ID: 38251667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular dynamics of genome editing with CRISPR-Cas9 and rAAV6 virus in human HSPCs to treat sickle cell disease.
    Xu L; Lahiri P; Skowronski J; Bhatia N; Lattanzi A; Porteus MH
    Mol Ther Methods Clin Dev; 2023 Sep; 30():317-331. PubMed ID: 37637384
    [No Abstract]   [Full Text] [Related]  

  • 7. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1.
    Schiroli G; Ferrari S; Conway A; Jacob A; Capo V; Albano L; Plati T; Castiello MC; Sanvito F; Gennery AR; Bovolenta C; Palchaudhuri R; Scadden DT; Holmes MC; Villa A; Sitia G; Lombardo A; Genovese P; Naldini L
    Sci Transl Med; 2017 Oct; 9(411):. PubMed ID: 29021165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
    Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
    Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome Engineering of Hematopoietic Stem Cells Using CRISPR/Cas9 System.
    Devaraju N; Rajendiran V; Ravi NS; Mohankumar KM
    Methods Mol Biol; 2022; 2429():307-331. PubMed ID: 35507170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing.
    McAuley GE; Yiu G; Chang PC; Newby GA; Campo-Fernandez B; Fitz-Gibbon ST; Wu X; Kang SL; Garibay A; Butler J; Christian V; Wong RL; Everette KA; Azzun A; Gelfer H; Seet CS; Narendran A; Murguia-Favela L; Romero Z; Wright N; Liu DR; Crooks GM; Kohn DB
    Cell; 2023 Mar; 186(7):1398-1416.e23. PubMed ID: 36944331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homology-Directed-Repair-Based Genome Editing in HSPCs for the Treatment of Inborn Errors of Immunity and Blood Disorders.
    Allen D; Kalter N; Rosenberg M; Hendel A
    Pharmaceutics; 2023 Apr; 15(5):. PubMed ID: 37242571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing CRISPR Efficiency and Measuring Its Specificity in HSPCs Using a Clinically Relevant System.
    Shapiro J; Iancu O; Jacobi AM; McNeill MS; Turk R; Rettig GR; Amit I; Tovin-Recht A; Yakhini Z; Behlke MA; Hendel A
    Mol Ther Methods Clin Dev; 2020 Jun; 17():1097-1107. PubMed ID: 32478125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient CRISPR/Cas9-Mediated Gene Knockin in Mouse Hematopoietic Stem and Progenitor Cells.
    Tran NT; Sommermann T; Graf R; Trombke J; Pempe J; Petsch K; Kühn R; Rajewsky K; Chu VT
    Cell Rep; 2019 Sep; 28(13):3510-3522.e5. PubMed ID: 31553918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-viral
    Byambaa S; Uosaki H; Ohmori T; Hara H; Endo H; Nureki O; Hanazono Y
    Mol Ther Methods Clin Dev; 2021 Mar; 20():451-462. PubMed ID: 33614821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing.
    Hou Y; Ureña-Bailén G; Mohammadian Gol T; Gratz PG; Gratz HP; Roig-Merino A; Antony JS; Lamsfus-Calle A; Daniel-Moreno A; Handgretinger R; Mezger M
    Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.
    Gundry MC; Brunetti L; Lin A; Mayle AE; Kitano A; Wagner D; Hsu JI; Hoegenauer KA; Rooney CM; Goodell MA; Nakada D
    Cell Rep; 2016 Oct; 17(5):1453-1461. PubMed ID: 27783956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Outcome of Homology-Directed Repair at the HBB Gene in HSC Using Alternative Donor Template Delivery Methods.
    Pattabhi S; Lotti SN; Berger MP; Singh S; Lux CT; Jacoby K; Lee C; Negre O; Scharenberg AM; Rawlings DJ
    Mol Ther Nucleic Acids; 2019 Sep; 17():277-288. PubMed ID: 31279229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease.
    De Ravin SS; Li L; Wu X; Choi U; Allen C; Koontz S; Lee J; Theobald-Whiting N; Chu J; Garofalo M; Sweeney C; Kardava L; Moir S; Viley A; Natarajan P; Su L; Kuhns D; Zarember KA; Peshwa MV; Malech HL
    Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.
    Pavani G; Fabiano A; Laurent M; Amor F; Cantelli E; Chalumeau A; Maule G; Tachtsidi A; Concordet JP; Cereseto A; Mavilio F; Ferrari G; Miccio A; Amendola M
    Blood Adv; 2021 Mar; 5(5):1137-1153. PubMed ID: 33635334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting.
    Charlesworth CT; Camarena J; Cromer MK; Vaidyanathan S; Bak RO; Carte JM; Potter J; Dever DP; Porteus MH
    Mol Ther Nucleic Acids; 2018 Sep; 12():89-104. PubMed ID: 30195800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.